Augtyro

Adult Dosing .

Dosage forms:  CAP: 40 mg, 160 mg

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

ROS1-positive non-small cell lung CA, locally advanced or metastatic

[160 mg PO bid]

Start: 160 mg PO qd x14 days; Info: do not open/crush/chew/dissolve cap

NTRK fusion-positive solid tumors, locally advanced or metastatic

[160 mg PO bid]

Start: 160 mg PO qd x14 days; Info: for patients with progressive disease; do not open/crush/chew/dissolve cap

renal dosing

[see below]

eGFR >30: no adjustment; eGFR <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1.1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined

Peds Dosing .

Dosage forms:  CAP: 40 mg, 160 mg

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

NTRK fusion-positive solid tumors, locally advanced or metastatic

[12 yo and older]

Dose: 160 mg PO bid; Start: 160 mg PO qd x14 days; Info: for patients with progressive disease; do not open/crush/chew/dissolve cap

renal dosing

[see below]

eGFR >30: no adjustment; eGFR <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1.1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined